ClinicalTrials.gg
RecruitingNCT07893444Updated Oct 26, 2026

BRIGHT-Child TB: Short-Course Treatment for Non-Severe Pulmonary Tuberculosis in Children

A Phase 2 interventional study of 4-month FDC-based regimen and 3-month BDCZ regimen in Tuberculosis, sponsored by Huashan Hospital. Recruiting at 13 sites in China. Open to participants aged 3 Months to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Huashan Hospital · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jul 2026, registered Oct 2026).
  • Started Jul 2026; still recruiting 3 months later.
Updated Oct 26, 2026Newly registeredGo to Updates ↓
Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
3 Months to 18 Years
Sex
All
01

Study summary

The goal of this Phase II, multicenter, open-label, randomized controlled trial is to evaluate the efficacy and safety of short-course treatment regimens for children with non-severe, drug-susceptible pulmonary tuberculosis.

The main questions it aims to answer are:

  • Do the 3-month bedaquiline, delamanid, contezolid, and pyrazinamide regimen (BDCZ) and the 4-month fixed-dose combination (FDC) regimen provide effective treatment, as measured by tuberculosis-free survival at 12 months after treatment initiation?
  • What are the safety profiles of the two short-course regimens, as measured by the incidence of grade 3 or higher adverse events?
  • How do the short-course regimens compare with the standard 6-month treatment regimen in terms of treatment success, treatment failure, recurrence, and tuberculosis-free survival during follow-up?

Researchers will compare the 3-month BDCZ regimen and the 4-month FDC regimen with the standard 6-month treatment regimen to evaluate their efficacy and safety in children with non-severe, drug-susceptible pulmonary tuberculosis.

Participants will be randomly assigned to one of three treatment groups and will receive the allocated regimen. They will undergo clinical assessments and safety monitoring during treatment, with follow-up to assess treatment outcomes, tuberculosis recurrence, and tuberculosis-free survival at 12, 18, and 24 months after treatment initiation.

Read the detailed description

Tuberculosis remains an important cause of morbidity in children. Shortening treatment duration while maintaining efficacy and safety is a key priority in the management of childhood tuberculosis. Evidence from previous studies has demonstrated that a 4-month treatment regimen can be effective for children with non-severe, drug-susceptible pulmonary tuberculosis. However, the implementation of short-course treatment in China remains challenging, partly because of limited availability of child-friendly formulations that support accurate dosing and treatment adherence.

Newer anti-tuberculosis drugs and combinations with potent bactericidal activity offer opportunities to further shorten treatment duration. However, clinical evidence supporting the use of these regimens in children with drug-susceptible tuberculosis remains limited. In addition, child-friendly fixed-dose combination (FDC) formulations may facilitate the implementation of short-course treatment by simplifying drug administration and improving dosing accuracy and adherence.

This Phase II, multicenter, open-label, randomized controlled trial will evaluate the efficacy and safety of two short-course treatment regimens in children with non-severe, drug-susceptible pulmonary tuberculosis. The study includes three treatment groups: a 3-month regimen containing bedaquiline, delamanid, contezolid, and pyrazinamide (BDCZ); a 4-month FDC-based regimen; and the standard 6-month treatment regimen as the control.

The study will assess whether the short-course regimens provide favorable treatment outcomes while maintaining an acceptable safety profile. Efficacy assessments will include tuberculosis-free survival, treatment success, treatment failure, and tuberculosis recurrence. Safety assessments will focus on adverse events, including grade 3 or higher adverse events.

Participants will receive the treatment assigned through randomization and will undergo clinical assessments and safety monitoring during treatment. Follow-up after treatment initiation will evaluate longer-term treatment outcomes, including tuberculosis recurrence and tuberculosis-free survival.

The findings of this study will provide clinical evidence on the potential use of shorter treatment regimens for children with non-severe, drug-susceptible pulmonary tuberculosis and may inform the development and implementation of more child-friendly treatment strategies.

02

Conditions studied

  • Tuberculosis

Keywords

  • children
  • pulmonary TB
  • non-severe
  • short-course treatment
03

In context

Tuberculosis

1,436 studies on the registry are indexed under Tuberculosis; 208 are open to participants now.

This study's planned enrollment of 90 is below the median of 150 across 963 interventional studies indexed under Tuberculosis.

Browse Tuberculosis studies →

Lead sponsor

Huashan Hospital is the lead sponsor of 247 studies on the registry; 105 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 3 months to 18 years.
  • Body weight of at least 3 kg.
  • Diagnosis of pulmonary TB according to the Chinese health industry standard WS 288-2017, Diagnosis of Tuberculosis, meeting the criteria for clinically diagnosed or bacteriologically confirmed tuberculosis.
  • Symptomatic, non-severe tuberculosis, meeting the following criteria: Chest imaging findings consistent with pulmonary tuberculosis, with the investigator determining that the child is eligible for treatment of non-severe tuberculosis, and no cavitation or signs of miliary tuberculosis; Uncomplicated tuberculous pleurisy, without empyema, pneumothorax, or bronchopleural fistula; Intrathoracic lymph node tuberculosis without airway obstruction, or peripheral lymph node tuberculosis; Low bacillary burden, defined as a negative acid-fast bacilli (AFB) smear result from a respiratory specimen. A positive or negative Xpert MTB/RIF result is permitted. A negative Xpert MTB/RIF result may be accepted as an alternative to a negative smear result. Respiratory specimen culture results may be positive or negative.
  • No previous anti-tuberculosis treatment, or previous treatment resulting in successful cure, with treatment having been completed more than 2 years before enrollment.
  • Willingness to undergo HIV antibody testing.
  • Willingness and ability to complete the assigned treatment and follow-up visits after treatment discontinuation.
  • Written informed consent obtained from a parent or legal guardian.
  • Residence and follow-up arrangements that allow the participant to complete the follow-up period within the study recruitment area.

Exclusion criteria

Exclusion Criteria:

  • Positive AFB smear result from a respiratory specimen or gastric aspirate. A positive smear result from a lymph node specimen is permitted.
  • Age younger than 3 months.
  • One or more of the following forms of TB: miliary TB, tuberculous meningitis, osteoarticular TB, abdominal or gastrointestinal TB, genitourinary TB, or reproductive system TB.
  • A non-tuberculosis condition that may affect treatment response or outcome assessment, including hepatic, renal, or cardiac disease; a corrected QT interval using Fridericia's formula (QTcF) greater than 450 ms in males or 470 ms in females; a condition requiring long-term immunosuppressive therapy; primary immunodeficiency; peripheral neuropathy; or cavitary disease.
  • Contraindication to any anti-tuberculosis drug included in the assigned treatment regimen.
  • Close contact within 6 months before enrollment with an adult diagnosed with drug-resistant tuberculosis, including tuberculosis with resistance to a single drug.
  • Diagnosis of drug-resistant TB before enrollment.
  • Critical illness.
  • Any other condition that, in the investigator's judgment, makes the child unsuitable for participation in the study.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    4FDC

    Drug: 4-month FDC-based regimen

  • Experimental
    3BDCZ

    Drug: 3-month BDCZ regimen

  • Active comparator
    2HRZ(E)/4HR

    Drug: Standard 6-month treatment regimen

Interventions

  • Drug4-month FDC-based regimen

    4-month fixed-dose combination (FDC) regimen

    Also known as: 4FDC

  • Drug3-month BDCZ regimen

    3-month bedaquiline, delamanid, contezolid, and pyrazinamide (BDCZ) regimen

    Also known as: 3BDCZ

  • DrugStandard 6-month treatment regimen

    Standard 6-month treatment regimen, namely 2HRZ(E)/HR.

    Also known as: 2HRZ(E)/4HR

06

What researchers measure

Primary outcomes

  1. Tuberculosis-free survival at 12 months

    Proportion of participants alive and free of tuberculosis at 12 months after treatment initiation.

    Time frame: 12 months after treatment initiation

  2. Incidence of grade 3 or higher adverse events

    Proportion of participants experiencing one or more grade 3 or higher adverse events during treatment.

    Time frame: From treatment initiation to the end of the assigned treatment regimen (3, 4, or 6 months)

Secondary outcomes

  1. Tuberculosis recurrence at 12 months

    Proportion of participants who experience tuberculosis recurrence within 12 months after treatment initiation.

    Time frame: 12 months after treatment initiation

  2. Treatment success and treatment failure at the end of treatment

    Proportions of participants classified as having treatment success or treatment failure according to the protocol-defined physician assessment at the end of the assigned treatment regimen.

    Time frame: At the end of the assigned treatment regimen (3, 4, or 6 months)

  3. Tuberculosis-free survival at 18 and 24 months

    Proportion of participants alive and free of tuberculosis at 18 and 24 months after treatment initiation.

    Time frame: 18 and 24 months after treatment initiation

  4. Tuberculosis recurrence at 18 and 24 months

    Proportion of participants who experience tuberculosis recurrence within 18 and 24 months after treatment initiation.

    Time frame: 18 and 24 months after treatment initiation

  5. Clinical outcomes at the end of follow-up

    Proportions of participants with favorable and unfavorable clinical outcomes at the end of follow-up, as defined in the study protocol.

    Time frame: 24 months after treatment initiation

07

Study locations

13 of 13 sites recruiting
  • Fuzhou Tuberculosis Prevention and Control Hospital of Fujian Province
    Fuzhou, Fujian, China
    • Yan Ruan · Contact
    • Yan Ruan · Principal investigator
    Recruiting
  • Guangzhou Chest Hospital
    Guangzhou, Guangdong, China
    • Shaomei Huang · Contact
    • Shaomei Huang · Principal investigator
    Recruiting
  • Guiyang Public Health Clinical Center
    Guiyang, Guizhou, China
    • Shusong Ruan · Contact
    • Shusong Ruan · Principal investigator
    Recruiting
  • Third People's Hospital of Liupanshui
    Liupanshui, Guizhou, China
    • Yiming Li · Contact · 3412426@qq.com
    • Yiming Li · Principal investigator
    Recruiting
  • Zunyi Infectious Diseases Hospital
    Zunyi, Guizhou, China
    • Youqian Chen · Contact
    • Youqian Chen · Principal investigator
    Recruiting
  • The Fifth People's Hospital of Suzhou
    Suzhou, Jiangsu, China
    • Xin Yu · Contact
    • Xin Yu · Principal investigator
    Recruiting
  • Ganzhou Fifth People's Hospital
    Ganzhou, Jiangxi, China
    • Pinghua Peng · Contact
    • Pinghua Peng · Principal investigator
    Recruiting
  • The Fourth People's Hospital of Qinghai Province
    Xining, Qinghai, China
    • Hongmei Zu · Contact
    • Hongmei Zu · Principal investigator
    Recruiting
  • Shandong Public Health Clinical Center
    Jinan, Shandong, China
    • Mingxia Sun · Contact
    • Mingxia Sun · Principal investigator
    Recruiting
  • Huashan Hospital
    Shanghai, Shanghai Municipality, China
    • Tao Li · Contact · litaokc@vip.163.com · 13816829726
    • Wenhong Zhang · Principal investigator
    • Tao Li · Sub investigator
    Recruiting
  • The First Affiliated Hospital of Shihezi University
    Shihezi, Xinjiang Uygur Autonomous Region, China
    • Songsong Xie · Contact
    • Songsong Xie · Principal investigator
    Recruiting
  • Hangzhou Red Cross Hospital
    Hangzhou, Zhejiang, China
    • Yuanyuan Chen · Contact
    • Yuanyuan Chen · Principal investigator
    Recruiting
  • The Children's Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    • Lisu Huang · Contact
    • Lisu Huang · Principal investigator
    Recruiting
08

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07893444
Lead sponsor
Huashan Hospital
Responsible party
Wen-hong Zhang (Professor, Huashan Hospital) — Principal investigator
First posted
Oct 26, 2026
Start date
Jul 8, 2026
Primary completion
Nov 30, 2027 (estimated)
Completion
Nov 30, 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

Tao Li
Contact
litaokc@vip.163.com
13816829726
Wenhong Zhang
Contact
zhangwenhong@fudan.edu.cn
52888123

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion